{"database": "openregs", "table": "documents", "is_view": false, "human_description_en": "where docket_id = \"FDA-2026-P-6737\" sorted by posted_date descending", "rows": [["FDA-2026-P-6737-0009", "FDA", "FDA-2026-P-6737", "Reference 7 - Incorporation of excess gadolinium into human bone from medical contrast agents", "Supporting & Related Material", "Background Material", "2026-06-15T04:00:00Z", 2026, 6, null, null, "2026-06-15T20:27:46Z", null, 0, 0, "09000064b932a303"], ["FDA-2026-P-6737-0012", "FDA", "FDA-2026-P-6737", "Reference 10 - Gadolinium-Based Contrast Agent Accumulation and Toxicity", "Supporting & Related Material", "Background Material", "2026-06-15T04:00:00Z", 2026, 6, null, null, "2026-06-15T20:27:55Z", null, 0, 0, "09000064b932a306"], ["FDA-2026-P-6737-0003", "FDA", "FDA-2026-P-6737", "Reference 1 - Gadolinium-Based Contrast Media Nephrotoxicity in Kidney Impairment", "Supporting & Related Material", "Background Material", "2026-06-15T04:00:00Z", 2026, 6, null, null, "2026-06-15T20:27:26Z", null, 0, 0, "09000064b932a273"], ["FDA-2026-P-6737-0008", "FDA", "FDA-2026-P-6737", "Reference 6 - Literature case analysis of nephrogenic systemic fibrosis induced by gadolinium-based contrast agents", "Supporting & Related Material", "Background Material", "2026-06-15T04:00:00Z", 2026, 6, null, null, "2026-06-15T20:27:43Z", null, 0, 0, "09000064b932a302"], ["FDA-2026-P-6737-0043", "FDA", "FDA-2026-P-6737", "Reference 41 - Long-Term Treatment with Gadopentetic Acid or Gadodiamide", "Supporting & Related Material", "Background Material", "2026-06-15T04:00:00Z", 2026, 6, null, null, "2026-06-15T20:29:44Z", null, 0, 0, "09000064b932a33d"], ["FDA-2026-P-6737-0040", "FDA", "FDA-2026-P-6737", "Reference 38 - Ultrastructural Evidence of Dermal Gadolinium Deposits", "Supporting & Related Material", "Background Material", "2026-06-15T04:00:00Z", 2026, 6, null, null, "2026-06-15T20:29:34Z", null, 0, 0, "09000064b932a33a"], ["FDA-2026-P-6737-0045", "FDA", "FDA-2026-P-6737", "Reference 43 - An initial investigation of serum cytokine levels in patients with gadolinium retention", "Supporting & Related Material", "Background Material", "2026-06-15T04:00:00Z", 2026, 6, null, null, "2026-06-15T20:29:50Z", null, 0, 0, "09000064b932a33f"], ["FDA-2026-P-6737-0030", "FDA", "FDA-2026-P-6737", "Reference 28 - Skin-Related Adverse Reactions in Gadolinium", "Supporting & Related Material", "Background Material", "2026-06-15T04:00:00Z", 2026, 6, null, null, "2026-06-15T20:28:56Z", null, 0, 0, "09000064b932a326"], ["FDA-2026-P-6737-0021", "FDA", "FDA-2026-P-6737", "Reference 19 -  Gadolinium-based contrast agent toxicity", "Supporting & Related Material", "Background Material", "2026-06-15T04:00:00Z", 2026, 6, null, null, "2026-06-15T20:28:25Z", null, 0, 0, "09000064b932a311"], ["FDA-2026-P-6737-0024", "FDA", "FDA-2026-P-6737", "Reference 22 -  Gadolinium deposition in bone tissues after contrast-enhanced", "Supporting & Related Material", "Background Material", "2026-06-15T04:00:00Z", 2026, 6, null, null, "2026-06-15T20:28:37Z", null, 0, 0, "09000064b932a314"], ["FDA-2026-P-6737-0044", "FDA", "FDA-2026-P-6737", "Reference 42 - Altered Functional Mitochondrial Protein Levels in Plasma", "Supporting & Related Material", "Background Material", "2026-06-15T04:00:00Z", 2026, 6, null, null, "2026-06-15T20:29:47Z", null, 0, 0, "09000064b932a33e"], ["FDA-2026-P-6737-0015", "FDA", "FDA-2026-P-6737", "Reference 13 - Prepubertal exposure to gadolinium", "Supporting & Related Material", "Background Material", "2026-06-15T04:00:00Z", 2026, 6, null, null, "2026-06-15T20:28:05Z", null, 0, 0, "09000064b932a309"], ["FDA-2026-P-6737-0018", "FDA", "FDA-2026-P-6737", "Reference 16 - Immediate adverse reactions to gadolinium-based MR contrast", "Supporting & Related Material", "Background Material", "2026-06-15T04:00:00Z", 2026, 6, null, null, "2026-06-15T20:28:15Z", null, 0, 0, "09000064b932a30e"], ["FDA-2026-P-6737-0037", "FDA", "FDA-2026-P-6737", "Reference 35 - The Impact of Gadolinium on Quantitative Myelin Metrics", "Supporting & Related Material", "Background Material", "2026-06-15T04:00:00Z", 2026, 6, null, null, "2026-06-15T20:29:23Z", null, 0, 0, "09000064b932a337"], ["FDA-2026-P-6737-0005", "FDA", "FDA-2026-P-6737", "Reference 3 - Gadolinium retention effect on macrophages", "Supporting & Related Material", "Background Material", "2026-06-15T04:00:00Z", 2026, 6, null, null, "2026-06-15T20:27:32Z", null, 0, 0, "09000064b932a275"], ["FDA-2026-P-6737-0041", "FDA", "FDA-2026-P-6737", "Reference 39 - Delineating toxicity mechanisms associated with MRI contrast", "Supporting & Related Material", "Background Material", "2026-06-15T04:00:00Z", 2026, 6, null, null, "2026-06-15T20:29:37Z", null, 0, 0, "09000064b932a33b"], ["FDA-2026-P-6737-0023", "FDA", "FDA-2026-P-6737", "Reference 21 -  Influence blocking by Gadolinium in Calcium Diffusion", "Supporting & Related Material", "Background Material", "2026-06-15T04:00:00Z", 2026, 6, null, null, "2026-06-15T20:28:33Z", null, 0, 0, "09000064b932a313"], ["FDA-2026-P-6737-0007", "FDA", "FDA-2026-P-6737", "Reference 5 - Concentration-Dependent Bidirectional Modification of Evoked Synaptic Transmission by Gadolinium", "Supporting & Related Material", "Background Material", "2026-06-15T04:00:00Z", 2026, 6, null, null, "2026-06-15T20:27:40Z", null, 0, 0, "09000064b932a301"], ["FDA-2026-P-6737-0010", "FDA", "FDA-2026-P-6737", "Reference 8 - Repeated gadolinium", "Supporting & Related Material", "Background Material", "2026-06-15T04:00:00Z", 2026, 6, null, null, "2026-06-15T20:27:50Z", null, 0, 0, "09000064b932a304"], ["FDA-2026-P-6737-0006", "FDA", "FDA-2026-P-6737", "Reference 4 - Gadolinium accelerates the migration of astrocyte via integrin signaling pathway", "Supporting & Related Material", "Background Material", "2026-06-15T04:00:00Z", 2026, 6, null, null, "2026-07-12T11:12:37Z", null, 0, 0, "09000064b932a300"], ["FDA-2026-P-6737-0019", "FDA", "FDA-2026-P-6737", "Reference 17 - Effects of Salicylate and Lanthanides on Outer Hair Cell Motility", "Supporting & Related Material", "Background Material", "2026-06-15T04:00:00Z", 2026, 6, null, null, "2026-06-15T20:28:19Z", null, 0, 0, "09000064b932a30f"], ["FDA-2026-P-6737-0011", "FDA", "FDA-2026-P-6737", "Reference 9 - Gadolinium Mitochondrial Toxicity", "Supporting & Related Material", "Background Material", "2026-06-15T04:00:00Z", 2026, 6, null, null, "2026-06-15T20:27:52Z", null, 0, 0, "09000064b932a305"], ["FDA-2026-P-6737-0017", "FDA", "FDA-2026-P-6737", "Reference 15 - Gadolinium based Contrast Agent Accumulates in the Brain Even in Subjects without Severe Renal Dysfunction", "Supporting & Related Material", "Background Material", "2026-06-15T04:00:00Z", 2026, 6, null, null, "2026-06-15T20:28:11Z", null, 0, 0, "09000064b932a30d"], ["FDA-2026-P-6737-0028", "FDA", "FDA-2026-P-6737", "Reference 26 - Neurotoxicity from intrathecal gadolinium", "Supporting & Related Material", "Background Material", "2026-06-15T04:00:00Z", 2026, 6, null, null, "2026-06-15T20:28:49Z", null, 0, 0, "09000064b932a324"], ["FDA-2026-P-6737-0031", "FDA", "FDA-2026-P-6737", "Reference 29 - Acute lung injury following gadolinium contrast", "Supporting & Related Material", "Background Material", "2026-06-15T04:00:00Z", 2026, 6, null, null, "2026-06-15T20:29:00Z", null, 0, 0, "09000064b932a327"], ["FDA-2026-P-6737-0033", "FDA", "FDA-2026-P-6737", "Reference 31 - Gadolinium-based contrast agent-induced neurotoxicity seeing is believing", "Supporting & Related Material", "Background Material", "2026-06-15T04:00:00Z", 2026, 6, null, null, "2026-06-15T20:29:07Z", null, 0, 0, "09000064b932a329"], ["FDA-2026-P-6737-0026", "FDA", "FDA-2026-P-6737", "Reference 24 -  Effects of Gadolinium-Based MRI Contrast", "Supporting & Related Material", "Background Material", "2026-06-15T04:00:00Z", 2026, 6, null, null, "2026-06-15T20:28:43Z", null, 0, 0, "09000064b932a322"], ["FDA-2026-P-6737-0004", "FDA", "FDA-2026-P-6737", "Reference 2 - Gadolinium-based MRI contrast agent effects on calcium signaling", "Supporting & Related Material", "Background Material", "2026-06-15T04:00:00Z", 2026, 6, null, null, "2026-06-15T20:27:30Z", null, 0, 0, "09000064b932a274"], ["FDA-2026-P-6737-0001", "FDA", "FDA-2026-P-6737", "Citizen Petition from Regina Sutton", "Other", "Citizen Petition", "2026-06-15T04:00:00Z", 2026, 6, "2026-06-15T04:00:00Z", null, "2026-06-15T20:27:13Z", null, 1, 0, "09000064b9329d15"], ["FDA-2026-P-6737-0022", "FDA", "FDA-2026-P-6737", "Reference 20 -  Human Hair as a Possible Surrogate Marker of Retained Tissue", "Supporting & Related Material", "Background Material", "2026-06-15T04:00:00Z", 2026, 6, null, null, "2026-06-15T20:28:30Z", null, 0, 0, "09000064b932a312"], ["FDA-2026-P-6737-0013", "FDA", "FDA-2026-P-6737", "Reference 11 - On the interaction of muscle actin with gadolinium", "Supporting & Related Material", "Background Material", "2026-06-15T04:00:00Z", 2026, 6, null, null, "2026-06-15T20:27:58Z", null, 0, 0, "09000064b932a307"], ["FDA-2026-P-6737-0016", "FDA", "FDA-2026-P-6737", "Reference 14 - Contrast-free identification of glioma blood-brain barrier status via generative diffusion AI and non-contrast MRI", "Supporting & Related Material", "Background Material", "2026-06-15T04:00:00Z", 2026, 6, null, null, "2026-06-15T20:28:09Z", null, 0, 0, "09000064b932a30c"], ["FDA-2026-P-6737-0036", "FDA", "FDA-2026-P-6737", "Reference 34 - Immediate Adverse Reactions to Gandolinium-Based MR Contrast Media", "Supporting & Related Material", "Background Material", "2026-06-15T04:00:00Z", 2026, 6, null, null, "2026-06-15T20:29:20Z", null, 0, 0, "09000064b932a336"], ["FDA-2026-P-6737-0042", "FDA", "FDA-2026-P-6737", "Reference 40 - The involvement of proinflammatory cytokines in nephrogenic systemic fibrosis", "Supporting & Related Material", "Background Material", "2026-06-15T04:00:00Z", 2026, 6, null, null, "2026-06-15T20:29:40Z", null, 0, 0, "09000064b932a33c"], ["FDA-2026-P-6737-0014", "FDA", "FDA-2026-P-6737", "Reference 12 - Skin-Related Adverse Reactions in Gadolinium-Based Contrast Agents-Induced Hypersensitivity", "Supporting & Related Material", "Background Material", "2026-06-15T04:00:00Z", 2026, 6, null, null, "2026-06-15T20:28:02Z", null, 0, 0, "09000064b932a308"], ["FDA-2026-P-6737-0002", "FDA", "FDA-2026-P-6737", "Acknowledgement Letter from FDA DMB to Regina Sutton", "Other", "Acknowledgement Letter/Receipt", "2026-06-15T04:00:00Z", 2026, 6, "2026-06-15T04:00:00Z", null, "2026-06-15T20:27:18Z", null, 0, 0, "09000064b9329d18"], ["FDA-2026-P-6737-0027", "FDA", "FDA-2026-P-6737", "Reference 25 - INDUCTION OF EXPRESSION OF PROFIBROTIC CYTOKINES", "Supporting & Related Material", "Background Material", "2026-06-15T04:00:00Z", 2026, 6, null, null, "2026-06-15T20:28:46Z", null, 0, 0, "09000064b932a323"], ["FDA-2026-P-6737-0020", "FDA", "FDA-2026-P-6737", "Reference 18 -  Deposition of Gadolinium in the Central and Peripheral Nervous Systems and Its Effects on Sensory", "Supporting & Related Material", "Background Material", "2026-06-15T04:00:00Z", 2026, 6, null, null, "2026-06-15T20:28:22Z", null, 0, 0, "09000064b932a310"], ["FDA-2026-P-6737-0034", "FDA", "FDA-2026-P-6737", "Reference 32 - Caught in the act Allergic-like reaction to", "Supporting & Related Material", "Background Material", "2026-06-15T04:00:00Z", 2026, 6, null, null, "2026-06-15T20:29:10Z", null, 0, 0, "09000064b932a32a"], ["FDA-2026-P-6737-0038", "FDA", "FDA-2026-P-6737", "Reference 36 - Effects of gadolinium", "Supporting & Related Material", "Background Material", "2026-06-15T04:00:00Z", 2026, 6, null, null, "2026-06-15T20:29:26Z", null, 0, 0, "09000064b932a338"], ["FDA-2026-P-6737-0029", "FDA", "FDA-2026-P-6737", "Reference 27 - Gadolinium during human pregnancy following administration of gadolinium chelate before pregnancy", "Supporting & Related Material", "Background Material", "2026-06-15T04:00:00Z", 2026, 6, null, null, "2026-06-15T20:28:52Z", null, 0, 0, "09000064b932a325"], ["FDA-2026-P-6737-0035", "FDA", "FDA-2026-P-6737", "Reference 33 - Acute respiratory distress syndrome after the use of gadolinium contrast agent.", "Supporting & Related Material", "Background Material", "2026-06-15T04:00:00Z", 2026, 6, null, null, "2026-06-15T20:29:16Z", null, 0, 0, "09000064b932a32b"], ["FDA-2026-P-6737-0039", "FDA", "FDA-2026-P-6737", "Reference 37 - Gadolinium Contrast Agent Deposition in Children", "Supporting & Related Material", "Background Material", "2026-06-15T04:00:00Z", 2026, 6, null, null, "2026-06-15T20:29:30Z", null, 0, 0, "09000064b932a339"], ["FDA-2026-P-6737-0025", "FDA", "FDA-2026-P-6737", "Reference 23 -  Assessment of gadolinium and iodine concentrations in kidney stones", "Supporting & Related Material", "Background Material", "2026-06-15T04:00:00Z", 2026, 6, null, null, "2026-06-15T20:28:40Z", null, 0, 0, "09000064b932a315"], ["FDA-2026-P-6737-0032", "FDA", "FDA-2026-P-6737", "Reference 30 - Comparison of Human Tissue Gadolinium Retention and Elimination between Gadoteridol and Gadobenate", "Supporting & Related Material", "Background Material", "2026-06-15T04:00:00Z", 2026, 6, null, null, "2026-06-15T20:29:03Z", null, 0, 0, "09000064b932a328"]], "truncated": false, "filtered_table_rows_count": 45, "expanded_columns": [], "expandable_columns": [[{"column": "docket_id", "other_table": "dockets", "other_column": "id"}, "title"]], "columns": ["id", "agency_id", "docket_id", "title", "document_type", "subtype", "posted_date", "posted_year", "posted_month", "comment_start_date", "comment_end_date", "last_modified", "fr_doc_num", "open_for_comment", "withdrawn", "object_id"], "primary_keys": ["id"], "units": {}, "query": {"sql": "select id, agency_id, docket_id, title, document_type, subtype, posted_date, posted_year, posted_month, comment_start_date, comment_end_date, last_modified, fr_doc_num, open_for_comment, withdrawn, object_id from documents where \"docket_id\" = :p0 order by posted_date desc limit 101", "params": {"p0": "FDA-2026-P-6737"}}, "facet_results": {"agency_id": {"name": "agency_id", "type": "column", "hideable": false, "toggle_url": "/openregs/documents.json?docket_id=FDA-2026-P-6737", "results": [{"value": "FDA", "label": "FDA", "count": 45, "toggle_url": "https://regs.datadawn.org/openregs/documents.json?docket_id=FDA-2026-P-6737&agency_id=FDA", "selected": false}], "truncated": false}, "document_type": {"name": "document_type", "type": "column", "hideable": false, "toggle_url": "/openregs/documents.json?docket_id=FDA-2026-P-6737", "results": [{"value": "Supporting & Related Material", "label": "Supporting & Related Material", "count": 43, "toggle_url": "https://regs.datadawn.org/openregs/documents.json?docket_id=FDA-2026-P-6737&document_type=Supporting+%26+Related+Material", "selected": false}, {"value": "Other", "label": "Other", "count": 2, "toggle_url": "https://regs.datadawn.org/openregs/documents.json?docket_id=FDA-2026-P-6737&document_type=Other", "selected": false}], "truncated": false}, "posted_year": {"name": "posted_year", "type": "column", "hideable": false, "toggle_url": "/openregs/documents.json?docket_id=FDA-2026-P-6737", "results": [{"value": 2026, "label": 2026, "count": 45, "toggle_url": "https://regs.datadawn.org/openregs/documents.json?docket_id=FDA-2026-P-6737&posted_year=2026", "selected": false}], "truncated": false}}, "suggested_facets": [{"name": "subtype", "toggle_url": "https://regs.datadawn.org/openregs/documents.json?docket_id=FDA-2026-P-6737&_facet=subtype"}, {"name": "open_for_comment", "toggle_url": "https://regs.datadawn.org/openregs/documents.json?docket_id=FDA-2026-P-6737&_facet=open_for_comment"}, {"name": "posted_date", "type": "date", "toggle_url": "https://regs.datadawn.org/openregs/documents.json?docket_id=FDA-2026-P-6737&_facet_date=posted_date"}, {"name": "comment_start_date", "type": "date", "toggle_url": "https://regs.datadawn.org/openregs/documents.json?docket_id=FDA-2026-P-6737&_facet_date=comment_start_date"}, {"name": "last_modified", "type": "date", "toggle_url": "https://regs.datadawn.org/openregs/documents.json?docket_id=FDA-2026-P-6737&_facet_date=last_modified"}], "next": null, "next_url": null, "private": false, "allow_execute_sql": true, "query_ms": 4.60134199965978, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}